We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · June 20, 2020

Tepotinib Plus Gefitinib in Patients With EGFR-Mutant NSCLC With MET Overexpression or Amplification and Acquired Resistance to Previous EGFR Inhibitors

The Lancet Respiratory Medicine

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Respiratory Medicine
Tepotinib Plus Gefitinib in Patients With EGFR-Mutant Non-Small-Cell Lung Cancer With MET Overexpression or MET Amplification and Acquired Resistance to Previous EGFR Inhibitor (INSIGHT Study): An Open-Label, Phase 1b/2, Multicentre, Randomised Trial
Lancet Respir Med 2020 May 29;[EPub Ahead of Print], YL Wu, Y Cheng, J Zhou, S Lu, Y Zhang, J Zhao, DW Kim, RA Soo, SW Kim, H Pan, YM Chen, CF Chian, X Liu, DSW Tan, R Bruns, J Straub, A Johne, J Scheele, K Park, JCH Yang, INSIGHT Investigators

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading